Keudell Morrison Wealth Management Has $308,000 Stake in Zoetis Inc. (NYSE:ZTS)

Keudell Morrison Wealth Management raised its stake in Zoetis Inc. (NYSE:ZTS) by 5.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,576 shares of the company’s stock after purchasing an additional 86 shares during the quarter. Keudell Morrison Wealth Management’s holdings in Zoetis were worth $308,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of ZTS. Asset Dedication LLC lifted its stake in Zoetis by 4.8% during the 2nd quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after acquiring an additional 54 shares in the last quarter. Forza Wealth Management LLC lifted its position in shares of Zoetis by 1.8% during the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after purchasing an additional 58 shares in the last quarter. Cherry Creek Investment Advisors Inc. boosted its holdings in Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the last quarter. L. Roy Papp & Associates LLP grew its position in Zoetis by 2.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after purchasing an additional 60 shares in the last quarter. Finally, Grove Bank & Trust grew its holdings in shares of Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS traded up $1.50 on Thursday, hitting $171.87. The company’s stock had a trading volume of 794,391 shares, compared to its average volume of 2,519,690. The company’s 50 day simple moving average is $188.46 and its 200-day simple moving average is $179.17. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm has a market cap of $77.87 billion, a P/E ratio of 32.02, a price-to-earnings-growth ratio of 2.68 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 52.59% and a net margin of 26.55%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.36 earnings per share. Analysts forecast that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 1.01%. Zoetis’s dividend payout ratio is currently 32.33%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.